Shortening of the ventricular fibrillatory intervals after administration of verapamil in a patient with Brugada syndrome and vasospastic angina

J Electrocardiol. 2006 Jul;39(3):331-5. doi: 10.1016/j.jelectrocard.2005.10.002. Epub 2006 Feb 28.


A 43-year-old man presented with electrocardiographic findings consistent with Brugada syndrome. Though the baseline coronary angiogram was normal, intracoronary infusion of ergonovine maleate caused complete occlusion of the left anterior descending and a 99% occlusion of the proximal right coronary artery, each relieved by intracoronary isosorbide dinitrate. Double extrastimuli delivered at the right ventricular outflow tract induced ventricular fibrillation terminated by a 200-J shock. Verapamil, 10 mg IV, increased ST-segment elevation and programmed stimulation repeated after the drug induced ventricular fibrillation with shorter F-F intervals and lower amplitude signals, which was not terminated by 200 J and required an additional 360-J shock. Ca2+ antagonism may have been adverse in this patient with Brugada syndrome because the drug has the potential to increase the voltage gradient through the right ventricle and to slow intraventricular conduction at very fast heart rates.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Angina Pectoris / complications
  • Angina Pectoris / diagnosis
  • Angina Pectoris / drug therapy*
  • Anti-Arrhythmia Agents / administration & dosage
  • Bundle-Branch Block / complications
  • Bundle-Branch Block / drug therapy*
  • Coronary Vasospasm / complications
  • Coronary Vasospasm / diagnosis
  • Coronary Vasospasm / drug therapy*
  • Electrocardiography / drug effects*
  • Humans
  • Male
  • Syndrome
  • Treatment Outcome
  • Ventricular Fibrillation / chemically induced*
  • Ventricular Fibrillation / diagnosis*
  • Verapamil / therapeutic use*


  • Anti-Arrhythmia Agents
  • Verapamil